Evolent Health (EVH)
(Real Time Quote from BATS)
$29.08 USD
-1.05 (-3.49%)
Updated Apr 24, 2024 01:06 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVH 29.08 -1.05(-3.49%)
Will EVH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EVH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVH
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
EVH: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 5th
How Much Upside is Left in Evolent Health (EVH)? Wall Street Analysts Think 59.66%
Best Momentum Stocks to Buy for November 20th
Other News for EVH
Evolent Health initiated with bullish view at Citi, here's why
In-Depth Examination Of 6 Analyst Recommendations For Evolent Health
Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)